Metuchen Pharmaceuticals, a men's health-focused specialty pharmaceutical company, agreed to merge with Neurotrope, a clinical-stage biotech company, resulting in a newly formed holding company to be renamed Petros Pharmaceuticals, which is expected to become a Nasdaq traded company. Upon completion, Neurotrope shareholders will own approximately 20% and Metuchen shareholders will own c. 80% of the combined company. "Following an extensive review of strategic alternatives, Neurotrope's Board of Directors believes that a merger with Metuchen and the formation of Petros offers shareholders the most compelling opportunity for a new direction to further enhance long-term value. Petros provides a platform to create the first publicly-traded biopharmaceutical company focused exclusively on FDA-approved treatments for men's health conditions, an underserved area of healthcare with significant growth potential. We believe Petros will be well-positioned financially and strategically to potentially accelerate the commercial growth of Stendra®, as well as advance its pipeline programs and opportunities," Charles S. Ryan, Neurotrope CEO.